Semaglutide·Novo Nordisk·Injectable pen

Ozempic

Ozempic® is an FDA-approved once-weekly injectable semaglutide pen manufactured by Novo Nordisk. FDA approved Ozempic® in December 2017 for the treatment of type 2 diabetes; it is not FDA-approved for weight loss (the FDA-approved semaglutide product for chronic weight management is Wegovy®). Weight Method does not dispense or prescribe brand-name Ozempic®. Our prescribing providers issue patient-specific prescriptions for compounded semaglutide, dispensed by U.S.-licensed 503A compounding pharmacies. Compounded semaglutide is not FDA-approved.

0.25mg0.5mg1mg2mgOnce weekly
Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Ozempic is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated June 2026Medically reviewed by licensed providers

Ozempic (semaglutide) is an FDA-approved GLP-1 medication for weight loss; in trials of the brand-name product, patients lost an average of 15-22% of their body weight. Weight Method does not dispense brand-name Ozempic — it offers compounded semaglutide, prescribed by licensed providers, from $199/month with virtual consultations and direct shipping.

Key Fact

Ozempic® (semaglutide 0.25-2mg) is an FDA-approved injectable manufactured by Novo Nordisk for type 2 diabetes (approved December 2017). The SUSTAIN clinical-trial program of brand-name Ozempic® reported weight changes of approximately 10-15% in subgroups (FDA labeling). Weight Method's compounded semaglutide program is dispensed at $154/month and is not FDA-approved.

Source: FDA approval data; SUSTAIN clinical trials

How does this medication work?

Ozempic® (brand-name semaglutide) activates GLP-1 receptors to suppress appetite, slow gastric emptying, and improve insulin sensitivity. Per FDA labeling, weight changes of approximately 10-15% have been reported in SUSTAIN-trial subgroups of brand-name Ozempic®.

Ozempic works by mimicking GLP-1 (glucagon-like peptide-1), a natural hormone released after eating that signals satiety to the brain. By binding to GLP-1 receptors in the hypothalamus, Ozempic reduces appetite, decreases food cravings, and helps patients feel full on smaller portions. It also slows gastric emptying, keeping food in the stomach longer and extending the sensation of fullness between meals. Additionally, Ozempic improves insulin sensitivity and helps regulate blood sugar levels, which is why it remains a cornerstone treatment for type 2 diabetes management.

What is it FDA-approved for?

FDA-approved for type 2 diabetes management (2017). The FDA-approved semaglutide product for chronic weight management is Wegovy®.

Ozempic is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is not FDA-approved for weight loss specifically -- that indication belongs to Wegovy, which contains the same active ingredient (semaglutide) at higher doses. However, physicians frequently prescribe Ozempic off-label for weight management in patients who meet clinical criteria, and the underlying mechanism for weight loss is identical.

What are the key facts you should know?

Once-weekly injection, 0.25mg to 2mg dose range, FDA-approved for type 2 diabetes, manufactured by Novo Nordisk, available since 2017.

Ozempic is available in four dose strengths: 0.25mg, 0.5mg, 1mg, and 2mg, administered once weekly via a pre-filled injectable pen. The medication was developed by Novo Nordisk and gained FDA approval in December 2017. In the SUSTAIN clinical trial program, Ozempic demonstrated significant A1C reductions alongside meaningful weight loss, with participants losing an average of 10-15% of body weight depending on the dose. Ozempic shares its active ingredient with Wegovy but is dosed differently and carries a diabetes-specific indication.

Why choose this treatment?

Brand-name Ozempic® has the longest real-world track record among FDA-approved GLP-1 products, with extensive data from the SUSTAIN clinical-trial program.

Ozempic® has one of the longest real-world track records among GLP-1 medications, with FDA approval since 2017 for type 2 diabetes. Patients seeking the FDA-approved brand-name Ozempic® obtain it through a retail pharmacy on a prescription from their treating provider. Weight Method does not dispense or prescribe brand-name Ozempic®. For patients who, after consultation with a Weight Method provider, choose compounded semaglutide as part of a chronic-weight-management program, Weight Method dispenses compounded semaglutide through U.S.-licensed 503A compounding pharmacies at $154/month all-inclusive. Compounded semaglutide is not FDA-approved.

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.

Starting at$199/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Compounded semaglutide. Once-weekly subcutaneous injection.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Compounded tirzepatide. Dual-action GLP-1/GIP, once-weekly subcutaneous injection.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Ozempic and Wegovy contain the same active ingredient -- semaglutide -- but they are approved for different conditions and dosed differently. Ozempic is FDA-approved for type 2 diabetes with a maximum dose of 2mg, while Wegovy is approved for chronic weight management with a maximum dose of 2.4mg. Your Weight Method provider will determine which semaglutide formulation and dosing schedule is appropriate for your goals.

Patients using Ozempic typically lose 10-15% of their body weight over 6-12 months, depending on the dose, adherence, and lifestyle factors. In the SUSTAIN 1 trial, patients on the 1mg dose lost an average of 12.3 lbs over 30 weeks. While Ozempic is not the highest-dose semaglutide option, many patients see clinically meaningful weight loss alongside improved metabolic health.

Yes. While Ozempic is FDA-approved specifically for type 2 diabetes, licensed providers frequently prescribe it off-label for weight management in patients who meet eligibility criteria (typically BMI of 30+ or BMI of 27+ with a weight-related health condition). Weight Method providers evaluate your full health profile to determine whether semaglutide is appropriate for your weight loss goals.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and stomach pain. These typically occur during the first few weeks of treatment or after dose increases and usually subside as your body adjusts. The gradual dose-escalation protocol -- starting at 0.25mg and increasing over weeks -- is designed specifically to minimize these effects.

No. Weight Method does not dispense or prescribe brand-name Ozempic®. Our prescribing providers issue patient-specific prescriptions for compounded semaglutide, which is dispensed by U.S.-licensed 503A compounding pharmacies. Weight Method's compounded semaglutide program is $154/month all-inclusive, including the medication, a licensed-provider evaluation, ongoing provider access, dose management, and home shipping. Compounded semaglutide is not FDA-approved and has not been reviewed by FDA for safety, efficacy, or manufacturing quality.

Ozempic comes in a pre-filled pen with a very thin, short needle. You inject it once per week under the skin of your abdomen, thigh, or upper arm. Most patients describe the injection as virtually painless and learn the technique in under a minute. Your Weight Method provider will walk you through the process during your initial consultation and is available for questions anytime.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

More about Ozempic

Generic Medication

Other Semaglutide Brands

Compare Ozempic

Ozempic by State